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1. Introduction 
Selective laser trabeculoplasty (SLT) is a relatively recent modality for treating patients with 
open-angle glaucoma and ocular hypertension. Similarly to argon laser trabeculoplasty, SLT 
uses laser energy to target the trabecular meshwork and lower intraocular pressure by 
increasing aqueous outflow. However, although argon laser trabeculoplasty has been used 
successfully for several years to treat open-angle glaucoma, it has been shown to cause 
collateral thermal damage to the trabecular meshwork (Kramer & Noecker, 2001). This often 
results in scarring and synechiae formation, which compromise the possibility of further re-
treatment. SLT uses a low-energy pulse (0.8 mJ to 1.2 mJ) and short pulse duration 
(approximately 3 nsec) in order to selectively target trabecular pigmented cells and reduce 
energy dissipation to the surrounding tissue. It was first reported in 1995 when Latina and 
Park irradiated a culture of pigmented and non-pigmented trabecular meshwork cells with 
different types of laser sources and analyzed their effect by electron microscopy (Latina & 
Park, 1995). They showed that selective cytotoxicity on pigmented trabecular meshwork 
cells could be achieved with pulse durations of 10 nsec and irradiance between 20 mJ/cm2 
and 1000 mJ/cm2 for the 532 nm, frequency-doubled Q-switched Nd:YAG laser. Fracture of 
melanin granules and rupture of lysosomal membranes in the pigmented trabecular 
meshwork cells and absence of ultrastructural damage in neighboring non-pigmented cells 
were revealed. 
2. Mechanism of action 
SLT technique employes frequency-doubled Q-switched Nd:YAG laser with a 532 nm 
wavelength emission. The pulse duration of 3 nsec, with an energy level of 0.6-1.0 mJ, grants 
a selective photothermolysis of the pigmented trabecular meshwork cells, sparing the 
surrounding non-pigmented cells. Morphologic changes induced by argon laser 
trabeculoplasty and SLT in cadaver eyes have been studied by Kramer and Noecker, with 
scanning and transmission electron microscopy (Kramer & Noecker, 2001). They found that 
argon laser trabeculoplasty lesions appear as ablation craters approximately 70 µm in 
diameter, with peri-lesional coagulative damage. The detachment of trabecular endothelial 
cells from the trabecular beams was also observed. Electron microscopy showed intact 
intracellular chromophore granules. The SLT morphologic effects appeared to be less 
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dramatic than argon laser trabeculoplasty. The beams of the trabecular meshwork were 
intact except rare crack-like defects between preserved beams. No coagulative damage or 
trabecular endothelial cells detachment was visible. Electron microscopy showed that many 
pigmented trabecular cells contained fragmented intracytoplasmic choromophore granules. 
Differences in the observed tissue effects between argon laser trabeculoplasty and SLT can 
be partly explained by differences in the energy delivered by the two techniques. The 
energy irradiance of a typical argon laser trabeculoplasty pulse of 0.1 second duration, 50-
μm spot diameter and 800 mW power is approximately 4 million mJ/cm2, whereas that of a 
SLT pulse of 0.8 mJ and 400-μm spot diameter is about 600 mJ/cm2. The typical SLT 
irradiation delivers light energy in very short nanosecond pulses. Therefore,  energy is 
deposited in the primary absorption sites so rapidly that it doesn’t reach the thermal 
relaxation time of the trabecular meshwork pigmented tissue. This results in a extremely fast 
temperature rise which causes the vaporization of water around melanosomes with the 
formation of microbubbles. Alvarado et al. proposed a possible explanation of SLT efficacy 
in reducing intraocular pression (Alvarado et al., 2005). The authors demonstrated the 
ability of nanosecond laser irradiation (similar to SLT) of trabecular meshwork cells to 
increase four-fold the permeability of the Schlemm’s canal endothelial cells. This 
phenomenon seems to be mediated by cytokines secreted by the irradiated trabecular 
meshwork cells. It’s been shown that adding cytokines like IL-8, IL-1ǂ, IL-1ǃ and TNF-ǂ to 
Schlemm’s canal endothelial cells, even in absence of irradiated trabecular meshwork cells, 
still increases cell permeability. Another study reported a 4- to 5- fold increase in monocyte 
presence in the trabecular meshwork after SLT treatment, enhancing both the outflow 
facility and the conductivity of Schlemm’s canal endothelial cells in vitro (Alvarado, Katz, 
Trivedi, & Shifera, 2010). Despite the above-mentioned evidences, the exact mechanism of 
SLT efficacy in lowering intraocular pressure in vivo remains unclear, thus requiring further 
investigations. 
3. Indications 
Any form of glaucoma having an intact trabecular meshwork and Schlemm’s canal with an 
altered outflow capability is a potential candidate for SLT. Thus, indications for SLT include 
primary open angle glaucoma, secondary glaucoma such as pseudoexfoliation glaucoma 
and pigmentary glaucoma. Secondary inflammatory glaucomas may be controindicated due 
to a chance of post-treatment anterior chamber reaction. Any angle-closure glaucoma is not 
a good candidate for SLT. 
4. Treatment 
4.1 Treatment parameters 
The settings for SLT are fixed except for the power. Spot size is 400 μm and the pulse 
duration is 3 nsec. The starting power depends on the degree of angle pigmentation. In a 
normally pigmented eye a 0.7-0.8 mJ power is generally sufficient. Highly pigmented eyes 
may require less energy (0.4-0.6 mJ) while for less pigmented ones powers up to 1.0 may be 
needed. The delivered energy has then to be adjusted increasing or decreasing the power 
level by 0.1 mJ until a threshold energy is reached. This endpoint consists in cavitation 
microbubbles formation that can be seen in the aqueous humor next to the trabecular 
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meshwork (champagne bubbles). Treatment should then be delivered 0.1 mJ below the 
threshold energy. The power level may be modified during the procedure if there is a 
significant variation in trabecular meshwork pigmentation. 
4.2 Treatment technique 
The treatment technique is similar to argon laser trabeculoplasty (Latina et al., 1998). 
Pretreatment with an alpha-agonist can be used to prevent early post-operative intraocular 
pressure spikes . After topical anesthesia, a Goldmann three-mirror lens or Latina SLT lens 
is used to focus a low-power laser aiming beam on the pigmented trabecular meshwork 
(Barkana and Belkin, 2007) . As coupling agent, methylcellulose or artificial tear gel are 
commonly used. Pilocarpine eye drops may be necessary in cases of narrow angle due to its 
ability to pull the peripheral iris away from the angle, improving the visualization of the 
trabecular meshwork. The size of the treatment spot is much larger than the one used in 
argon laser trabeculoplasty (typically a 50 μm spot) and covers entirely the antero-posterior 
width of the trabecular meshwork (Barkana and Belkin, 2007) . 
4.3 How much angle should be treated? 
Approximately 50 non-overlapping, confluent spots are applied to 180° of the angle 
circumference, or 100 spots to the full angle circumference. Some ophthalmologists prefer 
the 180° procedure according to the argon laser trabeculoplasty experiences, which showed 
a lower post-treatment intraocular pressure spike incidence. Nonetheless others go for a 
more extended procedure, treating 360° in a single session, considering SLT a safer 
procedure than argon laser trabeculoplasty. A study from Nagar et al did not show a 
significant increase of post-treatment intraocular pressure spike after full circumference 
angle treatment (Nagar, Ogunyomade, O'Brart, Howes, & Marshall, 2005). However, the 
authors reported a correlation between the angular extension treatment and its intraocular 
pressure lowering effect. This prospective, randomized clinical trial was conducted to 
compare 90°, 180°, and 360° SLT with latanoprost 0.005% for the control of intraocular 
pressure in ocular hypertension and open angle glaucoma. Thirty-nine eyes were 
randomized to receive latanoprost. Thirty-five eyes were randomized to the 90° SLT group, 
49 eyes to 180° SLT group, and 44 eyes to the 360° SLT group. The mean follow up was 10.3 
months. Spikes of intraocular pressure at 1 hour (5 mmHg or more) were seen in three eyes 
(9%) after 90° SLT, eight eyes (16%) after 180° SLT, and 12 eyes (27%) after 360° SLT. Mean 
intraocular pressure at 1 hour was significantly higher with 360° compared to 90° SLT 
treatments (p<0.05). In the 90° SLT group 12 eyes (34%) achieved a >20% intraocular 
pressure reduction. Whereas the same goal was obtained in the 65% and 82% in the 180° and 
360° groups, respectively. In a retrospective consecutive chart review, Shibata et al. 
evaluated the efficacy of 180° and 360° SLT in the adjunctive treatment of medically treated 
open angle glaucoma. After an average follow-up of 19.5 months (180° group) and 17.9 
months (360° group), they found that the 360° SLT showed a statistically higher intraocular 
pressure reduction as compared to the 180° SLT group. Moreover, a Kaplan-Meier survival 
analysis showed higher success rate after 360° SLT than after 180° SLT (Shibata et al., 2010) 
4.4 Post-treatment medications 
After the procedure, patients usually continue to take their preoperative glaucoma 
medications until the intraocular pressure is re-evaluated. Non-steroidal anti-inflammatory 
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eye drops are recommended for the post-treatment management. However, this last 
measure presents some controversial aspects. As mentioned above, the post-operative 
inflammation with its characteristic cytokine expression profile may play a pivotal role in 
the intraocular pressure-lowering effect of SLT via the enhancement of Schlemm’s 
endothelial cells permeability (Alvarado et al., 2005; Alvarado, Iguchi, Martinez, Trivedi, & 
Shifera, 2010). 
5. Efficacy 
The first pilot study evaluating the intraocular pressure lowering effect of SLT was 
conducted in 1998 (Latina et al., 1998). Fifty-three eyes with uncontrolled open angle 
glaucoma despite intraocular pressure-lowering medications or previous argon laser 
trabeculoplasty treatment, received 180° SLT and continued their pretreatment medical 
therapy. The patients were followed up for 26 weeks and a mean intraocular pressure 
reduction of 18.7% (4.6 mmHg) was reported. Lanzetta et al showed a higher efficacy with a 
IOP reduction of 40% by treating with 360° SLT (Lanzetta et al., 1999) Some randomized, 
controlled clinical trials compared SLT to argon laser trabeculoplasty and to medical 
therapy. Table 1 summarizes the efficacy results of controlled and uncontrolled studies. 
5.1 SLT vs argon laser trabeculoplasty 
SLT seems to be a valuable alternative to argon laser trabeculoplasty showing analogue 
efficacy, but being theoretically safer in terms of trabecular meshwork damages. There are 
several evidences supporting the SLT effectiveness through its comparison with argon laser 
trabeculoplasty. 
In a randomized clinical trial, Damji et al. compared argon laser trabeculoplasty and SLT 
capacity to lower intraocular pressure in eyes affected by open angle glaucoma with a 1 year 
follow up. They enrolled 176 eyes of 152 patients randomly assigning 89 eyes to 180° SLT 
(baseline intraocular pressure was 23,84 mmHg) and 87 to 180° argon laser trabeculoplasty 
(baseline intraocular pressure was 23.48 mmHg). Their study showed a non-significant 
difference between the two treatments arms. In the SLT group intraocular pressure was 
reduced by 5.86 mmHg, and in the argon laser trabeculoplasty group it was lowered by 6.04 
mmHg (p=0.846). No significant differences in IOP were also noticed during all the follow 
up time points preceding the 12 months. In the same study SLT was an effective option for 
pseudoexfoliation glaucoma too: twenty-three eyes in the argon laser trabeculoplasty group 
and 16 in the SLT group were affected by pseudoexfoliation glaucoma and the mean 
intraocular pressure reduction in the two subgroups was 5.4 mmHg and 5.7 mmHg 
respectively. The percentage of eyes reaching an intraocular pressure reduction ≥ 20 % at 12 
months was 59.7 % in the SLT group and 60.3 % in the argon laser trabeculoplasty  group 
confirming non significant differences in the two arms (Damji et al., 2006).  
Long-term efficacy was evaluated in a study by Juzych et al. They showed that argon laser 
trabeculoplasty and SLT have similar efficacy in reducing intraocular pressure at 5 years. 
One-hundred-ninety-five eyes with uncontrolled open angle glaucoma on maximally 
tolerated medications and no previous glaucoma surgery or iridectomy were studied.  
Forty-one eyes were treated once by 180° SLT, the remaining by 180° argon laser 
trabeculoplasty. Twenty-eight patients in the SLT group and 128 in the argon laser 
trabeculoplasty group had never been laser treated before entering the study. At the end of 
the 5 years follow up, 20 SLT and 40 argon laser trabeculoplasty patients were available for 
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Author 
SLT  
protocol 
Population Follow-up 
Baseline 
IOP 
mm Hg 
IOP 
reduction 
Mm Hg (%)
Treatment 
success criteria
Success %  Comments 
(Latina et al., 
1998) 
Nasal 
180° 
SLT 
53 eyes on 
MTMT or 
previous ALT 
26 weeks
(only 44 eyes)
24.6 4.6 (18%) IOP reduction
≥ 3 mmHg 
73% Results were 
similar in both 
previously ALT 
treated and 
MTMT  
(Lanzetta, 
Menchini, & 
Virgili, 1999) 
360° SLT 8 eyes of 6 
patients with 
POAG, some 
on MTMT 
6 weeks 26.6 ± 7 10.6 ± 5.2
(40%) 
NA NA
 
(Kajiya, 
Hayakawa, & 
Sawaguchi, 
2000) 
180° SLT 17 eyes of 10 
patients with 
POAG, 1 eye 
with PEXG 
6 months 22.8 6.7 (29%) NA NA
 
(Chen et al., 
2004) 
180° SLT
 
 
 
 
 
 
 
90° SLT
2 groups of 32 
patients with 
OHTN or 
OAG, some 
with previous 
ALT 
7 months 26.1 ± 1.7 6.16 (24%) in 
responders 
 
 
 
 
 
7.01 (28%) in 
responders
IOP controlled 
without 
retreatment or 
surgery at 7 
months 
59%
 
 
 
 
 
 
 
53%
Significant 
correlation 
between IOP 
reduction and 
TM 
pigmentation.   
(Gracner, 
2001) 
180° SLT 50 eyes with 
OAG 
6 months 22.5 5.06 ± 2.37 
(22.5%) 
IOP reduction
≥ 3 mmHg 
88%
 
(Hodge et al., 
2005) 
180° SLT 72 OAG on 
MTMT, some 
with previous 
ALT 
12 months 23.8 ± 4.9 5.8 IOP reduction 
of ≥ 20% after
1 year 
60% IOP reduction 
significantly 
related to higher 
baseline IOP, 
but not to all 
other factors 
examined 
(Damji, Shah, 
Rock, Bains, & 
Hodge, 1999) 
180° SLT
 
 
180° ALT 
2 groups of  
eyes with 
OAG 
6 months 22.8 ± 3.0
 
 
22.5 ± 3.6 
4.8 ± 3.4 
(21%) 
 
4.7 ± 3.3 
(21%)
NA NA
Similar IOP 
reduction by 
SLT and ALT 
(Damji et al., 
2006) 
180° SLT 2 groups of 
eyes with 
OAG
12 months 23.8 ± 4.9 6.1 ± 5.9 
(27%) 
IOP reduction
≥ 20% 
59.7 % Similar IOP 
reduction by 
SLT and ALT.  
(Martinez-de-
la-Casa et al., 
2004) 
180° SLT
 
 
 
 
 
180° ALT
2 groups of 20 
eyes with 
POAG no 
previous ALT 
6 months 24 ± 4.7
 
 
 
 
 
23.6 ± 3.8
5.4 (23%) IOP reduction
≥ 3 mmHg 
80%
 
 
 
 
 
85%
Similar IOP 
reducton by SLT 
and ALT 
troughout the 
study 
(Juzych et al., 
2004) 
180° SLT
 
 
 
 
 
 
180° ALT 
OAG on 
MTMT, 41 
treated  with 
SLT, 154 with 
ALT 
32.5 ± 15.9 
months 
23.9 ± 2.6
 
 
 
 
 
 
24.3 ± 4.1 
18%, 23%
and 27% in 
successful 
cases at 
1, 3, 5 yrs 
 
 
18%, 21% and 
23.5% for 
successful 
cases at 1, 3, 5 
yrs
IOP reduction
≥ 3 mm Hg 
without 
additional 
medication or 
surgery 
68%, 46% 
and 32% at 1, 
3 and 5 yrs 
 
 
 
 
54%, 30% 
and 31% at 1, 
3 and 5 yrs 
Success rates 
similar between 
ALT and SLT, 
between 
patients with or 
without prior 
ALT 
(Melamed et 
al., 2003) 
Nasal 
180° SLT 
45 eyes of 31 
patients with 
OAG or 
OHTN, 37 
newly 
diagnosed or 
after washout 
Range 3 - 24 
months 
25.5 ± 2.5 7.7 ± 3.5 
(30%) at last 
follow up 
IOP reduction
≥ 20% 
 
 
 
IOP controlled 
without topical 
medication at 
last follow-up
96%
 
 
 
 
93% 
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Author 
SLT  
protocol 
Population Follow-up 
Baseline 
IOP 
mm Hg 
IOP 
reduction 
Mm Hg (%)
Treatment 
success criteria
Success %  Comments 
(Lai, Chua, 
Tham, & Lam, 
2004) 
360° SLT 29 chinese 
patients with 
POAG 
5 years (82.8% 
completed 
follow-up) 
26.2 ± 4.2  8.6 ± 6.7 IOP reduction
≥ 21% without 
medications 
 
IOP reduction
≥ 21% on 
medications
72%
 
 
 
83% 
Similar IOP 
reduction by 
SLT and 
medications 
(Gracner, 
2002) 
Inferior 
180° SLT 
10 patients 
with PEXG 
 
 
 
10 patients 
with POAG
12 ± 5.5 
months 
 
 
 
13.5 ± 4.3 
months
23.6 ± 5.7
 
 
 
 
22.8 ± 2.4 
6.0 ± 3.3 
 
 
 
 
6.5 ± 2.8  
IOP reductions 
≥ 20% and no 
progressive VF 
or ON changes 
after 1 year 
70%
 
 
 
 
80% 
Results not 
statistically 
different 
between eyes 
with POAG and 
PEXG 
(Song et al., 
2005) 
90% had 
180° SLT
94 patients 
with OAG
10.5 months 17.6 2.1 IOP reduction
> 3 mmHg
32%
 
(Francis, 
Ianchulev, 
Schofield, & 
Minckler, 
2005) 
180° SLT 66 patients 
with 
medically 
controlled 
POAG or 
PEXG 
12 months 
(91% 
completed 
follow-up) 
Ability to 
decrease 
medications 
while 
maintaining 
target IOP 
87% 
discontinued 
a mean of 2.0 
medications 
at 6 months 
and 1.5 at 12 
months 
 
(Nagar et al., 
2005) 
Xalatan
 
 
 
 
 
 
 
 
 
 
90° SLT 
 
 
 
 
 
 
 
 
 
180° SLT 
 
 
 
 
 
 
 
 
 
360° SLT 
167 patients
with 
OHT or 
OAG 
newly 
diagnosed 
or medically 
controlled 
after 
washout 
 
10.3 months
 
 
29.3 IOP reduction ≥ 
20% 
 
 
IOP reduction ≥ 
30% with no 
additional 
medications 
 
 
 
IOP reduction ≥ 
20% 
 
 
IOP reduction ≥ 
30% with no 
additional 
medications 
 
 
IOP reduction ≥ 
20% 
 
 
IOP reduction ≥ 
30% with no 
additional 
medications 
 
 
IOP reduction ≥ 
20% 
 
 
IOP reduction ≥ 
30% with no 
additional 
medications
90%
 
 
 
78% 
 
 
 
 
 
 
34% 
 
 
 
11% 
 
 
 
 
 
65% 
 
 
 
48% 
 
 
 
 
 
82% 
 
 
 
59% 
 
(Cvenkel, 
2004) 
 
inferior
180° SLT 
 
44 eyes of 31
patients with 
medically 
controlled 
OAG 
25.57
(range 
22--34) 
 
25.6
(range 
22--34) 
 
4.8 mm Hg
(18.6%) 
at 6 months
4.4 mm Hg 
(17.1%) at 
12 months
IOP reduction
≥ 3 mm Hg 
 
66% at 3 
months 
 
79% at 6 
months 
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Author 
SLT  
protocol 
Population Follow-up 
Baseline 
IOP 
mm Hg 
IOP 
reduction 
Mm Hg (%)
Treatment 
success criteria
Success %  Comments 
63% at 3 
months 
(Kim & Moon, 
2000) 
 
Temporal 
or 
nasal 180° 
SLT 
 
16 eyes
(13 patients) 
with POAG 
 
12 months
(15 eyes) 
 
244 4.93 mm Hg
(20.2%) 
 
IOP reduction
≥ 3 mm Hg 
 
81% of eyes 
 
 
(Johnson, 
Katz, & Rhee, 
2006) 
 
360° SLT
 
132 eyes
(95 patients) 
with OAG 
 
3 months
 
20.9
 
3.74 ± 4.58
mm Hg 
(12.4%) 
 
IOP reduction
≥ 30% 
 
IOP reduction
21%-30% 
24%
 
 
43% 
 
 
(McIlraith et 
al., 2006) 
 
Latanopr
ost 
(26 eyes) 
 
inferior 
180° SLT 
(74 eyes) 
 
100 eyes with
newly 
diagnosed 
early OAG 
and OHT 
 
12 months
 
24.6
 
 
26.0 
 
7.7 mm Hg
(30.6%) 
 
8.3 mm Hg 
(31%) 
 
IOP reduction
≥ 30% 
 
IOP reduction
≥ 30% 
 
43%
 
 
55% 
No significant 
difference in 
IOP reduction 
between SLT 
and latanoprost 
(Zaninetti & 
Ravinet, 2008) 
180° or 
360° SLT 
 
36 eyes of 26 
patients (only 
36 completed 
24 mos f-up) 
with OAG 
(either OHT, 
POAG,PEXG 
or PG) among 
them 8 naïve 
eyes
2 yrs (36 eyes) 19.2± 4.7 3.3 mmHg 
(17%) 
≥3 mmHg IOP 
decrease  
 
≥20% IOP 
decrease 
48%
 
 
 
41% 
 
(Birt, 2007) 
inferior 
180° SLT 
after 
receiving 
360° ALT 
(27 eyes) 
 
 inferior 
180° SLT 
only 
(30 eyes) 
 
inferior 
180°ALT 
only 
(39 eyes)
96 eyes 
affected by 
OAG (POAG , 
PEXG or PG) 
1 yr 21.5 mmHg 
ALT+SLT 
 
 
 
22.9 mmHg 
SLT  
 
 
22.0 mmHg 
ALT  
4.8 mmHg 
(19.3%) 
ALT+SLT 
 
 
 
5.8 mmHg 
(23%) 
SLT 
 
 
5.6 mmHg 
(24%) 
ALT 
 
(Alvarado et 
al., 2005) 
IOP 
assesmen
t in the 
same 24 
eyes in 
three 
moments: 
 on PGA 
before 
SLT 
(PGA-
IOP)  
then  
off PGA 
before 
SLT 
(BASELI
NE-IOP) 
then  
after SLT 
(SLT-IOP)
24  eyes 90 days 15.9 mmHg
(PGA-IOP)
 
 
 
 
21.5 mmHg
(BASELINE
-IOP) 
6.6 mmHg
difference 
between SLT-
IOP and 
BASELINE-
IOP  
 
1 mmHg 
difference 
between SLT-
IOP and 
PGA-IOP 
PGA and SLT 
showed same 
ability in 
decreasing IOP 
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Author 
SLT  
protocol 
Population Follow-up 
Baseline 
IOP 
mm Hg 
IOP 
reduction 
Mm Hg (%)
Treatment 
success criteria
Success %  Comments 
(Shazly et al., 
2010) 
Nasal 
180°  SLT 
19 eyes with 
POAG 
 
 
 
 
 
 
 
 
8 eyes with 
PEXG 
27.1 months in 
POAG group
(3 
withdrawals 
by month 30)
 
 
20.4 months 
(4 
withdrawals 
by month 30)
23.3 
 
 
 
 
 
 
 
 
 
23.6  
  
5.7 
 
 
 
 
 
 
 
 
 
5.5 
 
Success if not 
return to 
baseline IOP 
values 
and/or not 
need for any 
further  
glaucoma- 
treatment either 
medical, laser or 
surgical 
77% at 30 to 
42 months 
 
 
 
 
 
 
 
74% at 30 to 
32 months 
 
 
75%  remain 
off 
medication 
for 2.5 yrs 
after SLT  
(either POAG 
or PEXG) 
 
 
(Cellini et al., 
2008) 
inferior 
180° SLT 
 
15 eyes with 
uncontrolled 
PEXG  
 
 
 
 
 
 
10 days
 
and 
 
30 days 
25.8 7.7 
 
 
 
0.4  
(return to 
baseline IOP
so 
trabeculecto
my was 
needed)
20% IOP 
decrease or 
visual field 
stabilization  
after SLT 
0%
 
 
 
SLT is not able 
to lower IOP in 
uncontrolled 
PEX G  due to 
it's inefficacy in 
reducing the 
MMP-2 /TIMP-
2 ratio. 
 
(Hong et al., 
2009) 
All eyes 
underwe
nt 360° 
SLT twice 
due to  
loss of 
IOP 
control at 
6 or more 
months 
after 
SLT1 
44 eyes with 
POAG or PEX 
or PG  
8 months 20.1  before 
SLT1 
 
19.5  before 
SLT2 
4  after SLT1
 
 
 
2.9  after 
SLT2 
Success if peak 
IOP reduction ≥ 
20% 
50% after 
SLT1 
 
 
43% after 
SLT2 
A second 360° 
SLT may be 
helpful when 
the first alone 
has failed in 
controlling IOP. 
(El Mallah et 
al., 2010) 
4 eyes 
180° SLT 
 
27 eyes 
360° SLT 
31 eyes with 
normal 
tension 
glaucoma 
(NTG) 
12 months
extended, if 
necessary, 
until 3 post 
SLT IOP 
measures were 
obtained
14.3 2.1 NA NA
Intervisit IOP 
variation was 
also reduced by 
SLT. 
SLT: selective laser trabeculoplasty; MTMT: maximally tolerated medical therapy;ALT: argon laser trabeculoplasty; IOP: intraocular 
pressure; POAG: primary open angle glaucoma; PEXG: pseudoexfoliation glaucoma; OHT: ocular hypertension; OAG: open angle 
glaucoma; PG: pigmentary glaucoma; PGA: prostagandin analogue; NTG: normal tension glaucoma;  
 
 
 
 
 
 
 
Table 1. Summary of SLT efficacy studies in peer-reviewed journals 
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evaluation and intraocular pressure reduction did not significantly differ being 27.1 ± 21.4 
% in the SLT group and 23.5 ± 25.2 % in the argon laser trabeculoplasty group (p=0.75). In 
the SLT group IOP reduction was 18.1 ± 10.2 % and 23.4 ± 13.2 % at 1 and 3 years, 
respectively. In the argon laser trabeculoplasty group IOP reduction was 18.1 ± 18.9 % at 1 
year and 20.8 ± 15.6 % at 3 years. Both the 1 year (p=0.99) and the 3 years (p=0.56) 
intraocular pressure percentage reduction were non significantly different. Another 
success criterion was considered an intraocular pressure reduction ≥ 20%. This was 
observed in 58% at 1 year, 38% at 3 years and 31% at 5 year in the SLT group and 46%, 
23%, 13% in the argon laser trabeculoplasty group at the same follow up times. All the 
mentioned results were achieved with no need of further laser irradiation, medications or 
surgical treatments and demonstrated a substantially equal efficacy between argon laser 
trabeculoplasty and SLT. 
5.2 SLT vs medical therapy 
SLT may not only be an option for those patients not responding to medications, but it may 
also be considered a first line alternative as it far less demanding in terms of compliance. 
In a prospective randomized 6-month follow-up study, Nagar et al. evaluated SLT and 
latanoprost on 40 eyes affected by either open angle glaucoma or ocular hypertension. 
Twenty eyes underwent SLT and 20 were treated with a latanoprost. Only 30 patients 
completed the follow up. Mean intraocular pressure reduction at 6 months was 6.2 mm Hg 
in the SLT eyes and 7.8 mm Hg in the latanoprost group.  A 20% intraocular pressure 
reduction at was reached in 75% of eyes of the SLT group and 73% of the latanoprost group. 
Both SLT and latanoprost have been shown to significantly reduce IOP fluctuation. Success 
in fluctuation reduction was 50% after SLT and 83% in the latanoprost group. Forthy-one 
percent and 64% reduction in IOP fluctuation was achieved after treatment with SLT or  
latanoprost, respectively. (Nagar et al., 2009). 
Alvarado et al. also provided evidences of a similar efficacy of prostaglandin analogue eye 
drops and SLT in reducing intraocular pressure. Non-significant differences in IOP were 
observed in 24 eyes sequentially exposed to the two treatments at different times and after a 
washout phase. Prostaglandin analogue and SLT reduced intraocular pressure by 5.58 
mmHg (25.37%) and 6.6 mmHg (29.93%) from the baseline respectively (Alvarado et al., 
2005). 
5.3 Long-term follow-up 
SLT long-term success versus argon-laser trabeculoplasty has been investigated by Damji et 
al (Damji et al., 2006). No statistical significant difference was found between patients 
randomized in the argon laser trabeculoplasty group and the patients randomized in the 
SLT group over 12 months. Juzych et al confirm these results over a 5-year follow-up period 
(Juzych et al., 2004). So, these data indicate that, despite the lack of a microscopically evident 
damage to the trabecular meshwork, SLT is at least as effective as argon-laser 
trabeculoplasty in reducing intraocular pressure in the long term.  
6. Adverse events and safety profile 
Most studies report a relatively lower side effects rate of SLT compared with argon-laser 
trabeculoplasty, which can be ascribed to significantly lower energies delivered to the ocular 
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tissues. The most common complications observed after SLT are post-operative intraocular 
pressure spikes, anterior chamber inflammation and ocular discomfort. 
6.1 Intraocular pressure spikes 
The overall incidence of intraocular pressure spikes following 360° SLT is expected to be 
lower than after ALT, ranging from 3 to 10%. Intraocular pressure should be measured 1 
hour after the procedure. An intraocular pressure increase of more than 5 mmHg should be 
considered significant and treated with additional topical or oral glaucoma medications. In 
order to prevent the occurrence of this complication, some authors suggest pre-medication 
with alpha-agonist and pilocarpine drops. The occurrence of intraocular pressure spike in 
heavily pigmented angles seems to be more frequent. Lower SLT energy levels have been 
proposed for such patients by some authors (Harasymowycz et al., 2005). In some cases of 
pseudoexfoliation glaucoma there might be an increased risk of intraocular pressure spikes 
following SLT. Cellini et al. reported intraocular pressure spikes in 15 patients affected by 
pseudoexfoliative glaucoma. This failure was demonstrated to correlate with a decreased 
ratio between tissue inhibitor metalloproteinase and matrix metalloproteinases 
concentrations (TIMP-2/MMP-2) in the aqueous humor (Cellini, Leonetti, Strobbe, & 
Campos, 2008). 
6.2 Anterior chamber inflammation 
The inflammatory response triggered by SLT may be responsible for anterior chamber 
reaction. This complication, including cells, flares and conjunctival injection has been 
commonly reported in several studies, with an incidence up to 83% of the first report from 
Latina. However it was always a transient event with no sequelae. SLT-related hypema has 
been anecdotally reported (Rhee, Krad, & Pasquale, 2009; Shihadeh, Ritch, & Liebmann, 
2006). 
6.3 Ocular discomfort 
During or after the procedure, ocular discomfort or even pain can occur. Latina et al. 
reported post SLT discomfort in 15% of the treated eyes. Pain scores after SLT where 
recorded by Martinez-de-la-Casa et al. and showed to be significantly lower than post-argon 
laser trabeculoplasty scores during the first 24 hours (Martinez-de-la-Casa et al., 2004). In a 
study comparing topical latanoprost to SLT, 39% of patients complained of ocular 
discomfort after the laser procedure, as compared to 0% of cases after topical medication 
(Nagar et al. 2005).      
7. Specific cases 
7.1 Pigmentary glaucoma 
There is some evidence showing a correlation between the degree of angle pigmentation and 
the effectiveness of SLT (Chen, Golchin, & Blomdahl, 2004). A study by Melamed included 3 
cases of pigmentary glaucoma; in these patients SLT produced an intraocular pressure 
reduction in 24% of eyes. (Melamed, Ben Simon, & Levkovitch-Verbin, 2003) Damji et al. 
obtained an intraocular pressure reduction of 5.6 mmHg in 5 pigmentary glaucoma patients 
treated with SLT after 12 months (Damji et al., 2006). On the contrary, Harasymowicz et al. 
www.intechopen.com
 
Selective Laser Trabeculoplasty 
 
267 
reported an intraocular pressure elevation in 3 patients included into the study and affected 
by pigmentary glaucoma (Harasymowycz et al., 2005).   
7.2 Pseudoexfoliation glaucoma 
SLT can be considered as a safe and effective method of therapy for pseudoexfoliation 
glaucoma similarly to other types of open angle glaucoma. In a small prospective trial, 
Gracner et al compared the results of 180° SLT treatment in patients with primary open 
angle glaucoma and patients with pseudoexfoliation glaucoma. After 18 months, there was a 
comparable IOP reduction between the 2 groups (Gracner, 2001). Shazly et al. confirmed 
these data in a study comparing the SLT results on 19 eyes with primary open-angle 
glaucoma and 18 eyes affected by pseudoexfoliation glaucoma (Shazly, Smith, & Latina, 
2010). Previously, also Melamed and Chen et al had similar findings (Chen et al., 2004; 
Melamed et al., 2003). 
7.3 Prior argon laser trabeculoplasty treatment 
SLT represent a practicable option in eyes previously treated with argon-laser 
trabeculoplasty. Some studies suggest that SLT is not associated with unfavorable outcomes 
in eyes with prior argon-laser trabeculoplasty and that the intraocular pressure-lowering 
efficacy is comparable to laser-naïve eyes. Latina et al. reported an intraocular pressure 
reduction of 5 mmHg or more in 40% of eyes that had not undergone previuos 
trabeculoplasty and 57% in those with previous argon laser trabeculoplasty (Latina et al., 
1998). Song et al. found no differences in the success rate between laser-naïve eyes and eyes 
previously treated with argon-laser trabeculoplasty (Song et al., 2005). Similarly, Birt did not 
find statistically significant differences in outcomes between patients previously treated 
with 360° argon-laser trabecuoplasty and laser-naïve eyes (Birt, 2007). 
7.4 Primary angle closure with persistent intraocular pressure elevation after 
iridotomy 
A report from Ho et al (Ho et al., 2009) showed that SLT might be an option for patients 
with primary angle closure glaucoma that underwent a successfully opening of the irido-
trabecular angle with peripheral laser iridotomy and persistent intraocular pressure 
elevation (≥21 mmHg). Sixty patients were enrolled in the study and were treated with SLT 
if at least 90° of pigmented trabecular meshwork was visible. During a study period of 6 
months, an intraocular pressure reduction of more than 20% was obtained in 54% of cases. 
No statistically significant correlation was found between the degree of angle treated and 
the amplitude of intraocular pressure lowering effect. 
7.5 Normal tension glaucoma 
El Mallah et al investigated SLT effectiveness on normal tension glaucoma. In their study 
they observed not only a post SLT reduction of the mean intraocular pressure, but also a 
narrowing of the intraocular pressure inter-visit variation. Both these values were 
significantly reduced. The mean intraocular pressure reduction was 2.1 mmHg. The 
intraocular pressure inter-visit variation was evaluated by considering the range and the 
standard deviation of multiple intraocular pressure measurements performed on each eye 
preceding and following SLT by approximately 12 months. Both these two parameters were 
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significantly diminished after SLT: by 4.5 and 1.9 mm Hg respectively. The authors stress 
the importance to record the mentioned intraocular pressure intervisit variation parameters 
in every patient undergoing SLT due to their correlation to the glaucoma progression (El 
Mallah, Walsh, Stinnett, & Asrani, 2010). 
7.6 Steroid-induced ocular hypertension 
SLT has been shown to effectively reduce intraocular pressure in patients with intravitreal 
and subtenon triamcinolone acetonide-induced intraocular pressure elevation (Baser & 
Seymenoglu, 2009; Pizzimenti, Nickerson, Pizzimenti, & Kasten-Aker, 2006; Rubin, 
Taglienti, Rothman, Marcus, & Serle, 2008; Yuki et al., 2010). However the role of SLT in 
post-steroid hypertension is still controversial due to the fact that it is non clear whether the 
lowering effect is more attributable to SLT or to the physiological drug wash out.   
7.7 Pseudophakic glaucoma 
SLT has been shown effective in pseudophakic  glaucoma (Nagar, Shah, & Kapoor, 2010). 
Furthermore Werner et al. have not found any difference in SLT efficacy between phakic 
and pseudophakic eyes (Werner, Smith, & Doyle, 2007). 
7.8 Glaucoma after penetrating keratoplasty 
Nakakura et al. successfully treated with SLT a medication-resistant IOP elevation following 
penetrating keratoplasty. The decrease in IOP was stable at 6 months and no adverse effect 
or graft rejection was recorded (Nakakura, Imamura, & Nakamura, 2009). 
8. Is SLT repeatable? 
When patients treated with argon laser trabeculoplasty require a repeated treatment, this is 
usually limited by complications such as intraocular pressure spikes and sustained 
intraocular pressure elevation. SLT delivers less energy to the trabecular meshwork and is 
non-destructive in nature, for these reasons multiple treatments are possible. Repeat 
treatment with SLT has been found to be safe and may be beneficial in some patients. Hong 
et al, described the results obtained repeating SLT on eyes previously treated with 360° SLT 
that had lost its efficacy. They found that repeating SLT is effective in reducing intraocular 
pressure. The mean intraocular pressure reduction at 8 months after the first and second 
procedure did not significantly differ, being 4 mmHg and 2.9 mmHg, respectively (Hong et 
al., 2009). 
9. Conclusions 
SLT can be considered a valuable alternative to medical therapy in the management of open 
angle glaucoma. According to the most recent findings, SLT should not only applied when 
medical therapy fails but as a first-line treatment. SLT has been found to be equally 
efficacious as prostaglandin analogues in reducing intraocular pressure as a primary 
treatment option in open angle glaucoma and ocular hypertension (McIlraith, Strasfeld, 
Colev, & Hutnik, 2006) with a good safety profile. Furthermore, this treatment results in 
significant decrease in the amplitude of diurnal intraocular pressure fluctuation (Kothy, 
Toth, & Hollo, 2010) which is related to glaucoma damage progression. The application of 
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this therapeutic modality is supported by a lack of trabecular meshwork injury that allows 
re-treatments. Eliminating the need for topical medications, SLT can minimize patient 
noncompliance and result in appropriate intraocular pressure control. Thus, it can also be a 
good choice for patients who are allergic to all types of topical medications without 
interfering with the success of future surgery (Gavric, Gabric, Dekaris, Bohac, & Draca, 
2010).  
The efficacy results, the effect duration and the good safety profile, might set SLT treatment 
as “gold standard” first-line therapy for open angle glaucoma,  in the near future. 
A better comprehensive of SLT mechanism of action is needed, as well as the research for 
new laser sources to better target  the trabecular meshwork cells, obtaining the desired effect 
with even less damage (Titanium Sapphire Trabeculoplasty: TiSalt 790nm, described by 
Goldenfeld and al.,2009).  
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